"25x-NBOMe" type molecules - Available information on the diffusion of a class of NPS in France

 

epfammx6.jpg

Memo, OFDT, 25 p.
June 2017

Within the vast category of new psychoactive substances, 25x-NBOMe or NBOMe represents a group of compounds in the phenethylamine family, which mainly has a hallucinogenic and psychedelic effect in particular.

These compounds, which are sometimes sold and used instead of LSD, have emerged on the French market over the past five years.

Based on the different activities carried out by the TREND-SINTES schemes and the I-TREND European project, this summary attempts to explain how 25x-NBOMe were able to attract obvious interest among certain users. It describes the way in which these substances have established a presence in France, according to a relatively symbolic diffusion pattern for new hallucinogenic substances. This analysis also focuses on the prospects for changes and the limits of their presence on French territory. Lastly, it presents and describes their inherent challenges and problems, particularly in relation to health.


Authors : Magali Martinez, Agnès Cadet-Taïrou,Thomas Néfau with the TREND network coordinators

Download the PDF file (518 Ko)

 

 

 

 

 

 

 

 

Drugs in Europe


2017 EMCDDA European Drug Report

miniEDR2017EN.jpgWhat do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions are explored in the 2017 EMCDDA European Drug Report.

  Country drug reports 2017

miniCountryProfiles.jpgDeveloped by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.